16 September 2026 note archive · Item
Tirzepatide as an adjunct in T1D: review notes
These archived notes document the scope reviewed on 16 September, including source-access limits. They do not cover later changes or newly added records. They are not independent clinical certification or a guarantee that every claim was verified.
Read the item evidence page →Thriving evidence review — 16 September 2026
Record: Tirzepatide as an adjunct in T1D
Scope and findings:
- Corrected blanket any-T1D-use-offlabel statement: obesity eligibility differs from T1D glycemic indication. Registry dates checked separately below.
Primary sources checked:
Limits: The review is restricted to the scopes above. Historical efficacy estimates, editorial scoring and country-specific access were not fully reverified unless expressly stated. A manufacturer or conference report retains that evidence level.